STOCK TITAN
  1. Home
  2. News
  3. CHRS

Coherus Biosciences Inc - CHRS STOCK NEWS

Welcome to our dedicated news page for Coherus Biosciences (Ticker: CHRS), a resource for investors and traders seeking the latest updates and insights on Coherus Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Coherus Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Coherus Biosciences's position in the market.

News
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Rhea-AI Summary
Coherus BioSciences, Inc. announces the presentation of clinical data for CHS-114 at the 2024 ASCO Annual Meeting. The presentation will cover the Phase 1 study results of the anti-CCR8 cytolytic antibody in patients with advanced solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
Rhea-AI Summary
Coherus BioSciences, Inc. presents preclinical data for CHS-1000, a novel ILT4 monoclonal antibody, at the 2024 AACR Annual Meeting. The data demonstrates CHS-1000's potential to reverse myeloid cell-mediated immunosuppression in the tumor microenvironment, activate an inflammatory immune response, and enhance antitumor responses with immunotherapy. The company plans to file the CHS-1000 IND in Q2 2024 and advance it into clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.29%
Tags
clinical trial
-
News
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
Rhea-AI Summary
Coherus BioSciences, Inc. (CHRS) reports strong financial results for Q4 2023 and FY 2023, with net revenue of $91.5 million and $257.2 million, respectively. Key highlights include UDENYCA® net sales of $36.2 million and CIMERLI® net sales of $52.4 million in Q4. The company successfully launched LOQTORZI™ and UDENYCA ONBODY™ in Q1 2024. However, a 30% workforce reduction for 2024 was initiated on March 7, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.65%
Tags
earnings
News
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
Rhea-AI Summary
Coherus BioSciences, Inc. announces the release of its fourth quarter and full year 2023 financial results on March 13, 2024. The management team will host a conference call and webcast to discuss the results and provide a business update. Investors can access the webcast and related materials on the Coherus website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
conferences earnings
-
News
Coherus Completes Divestiture of Ophthalmology Franchise
Rhea-AI Summary
Coherus BioSciences, Inc. (NASDAQ: CHRS) completes the divestiture of its CIMERLI ophthalmology franchise through the sale of Coherus Ophthalmology LLC to Sandoz, Inc. for $170 million in upfront cash. The transaction strengthens Coherus' capital structure and strategic focus in oncology, allowing the company to advance its immuno-oncology pipeline and launch LOQTORZI in nasopharyngeal carcinoma and UDENYCA ONBODY.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.81%
Tags
none
-
News
Coherus BioSciences Announces New Employment Inducement Grants
Rhea-AI Summary
Coherus BioSciences, Inc. granted options to purchase 170,000 shares of common stock to newly hired employees. The options have an exercise price of $2.59 per share, based on the closing trading price on the grant date. The grants were made under the 2016 Employment Commencement Incentive Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
none
News
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
Rhea-AI Summary
Coherus BioSciences, Inc. launches UDENYCA ONBODY, an innovative on-body injector for pegfilgrastim-cbqv, with a five-minute delivery time and a retractable needle mechanism for cancer patients. Positive feedback from providers and patients indicates growing demand for UDENYCA, offering a convenient and safe treatment option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.25%
Tags
none
-
News
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
Rhea-AI Summary
Coherus BioSciences, Inc. has revised its loan agreement with Pharmakon Advisors, LP, reducing the principal balance to $75 million upon a projected paydown of $175 million in Q2 2024. The revenue covenant has also been reduced to $125 million, and the term loan annual interest expense is expected to be reduced by approximately 70%. This agreement follows the divestiture of the ophthalmology franchise to Sandoz, and the company aims to lower its projected annual interest payments significantly.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.94%
Tags
none
-
News
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
Rhea-AI Summary
Coherus BioSciences, Inc. (NASDAQ: CHRS) has announced the divestiture of its CIMERLI ophthalmology franchise to Sandoz for $170 million in upfront, all-cash consideration. The transaction aims to allow Coherus to focus on its core therapeutic area, oncology, by reducing debt, interest costs, and overhead costs. The company's oncology assets include the UDENYCA franchise, LOQTORZI, and an immuno-oncology pipeline of next-generation tumor microenvironment oncology drug candidates. The closing is anticipated in the first half of 2024, subject to certain closing conditions and approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.74%
Tags
none
News
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
Rhea-AI Summary
Coherus BioSciences, Inc. presents promising data from the lead-in portion of the Phase 2 clinical trial evaluating casdozokitug in combination with atezolizumab and bevacizumab for the treatment of liver cancer. The data demonstrates a 38% objective response rate, including three complete responses, and supports continued evaluation of casdozokitug with VEGF and PD-(L)1 blockade in HCC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
clinical trial
Stock CHRS logo
Coherus Biosciences Inc

Nasdaq:CHRS

CHRS Rankings

#3644 Ranked by Market Cap
#5124 Ranked by Stock Gains
N/A Ranked by Dividends

CHRS Stock Data

251.35M
103.90M
1.35%
77.99%
20.8%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Redwood City

About CHRS

coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp